Given a context passage, generate a question from the passage such that its answer is shortest continous span from the passage.
--------
Question: What could make Michael Jordon, one of the greatest basketball players in history, shed tears? It was when he became a member of the Basketball Hall of Fame on September 11. The hall is in Springfield, Massachusetts and honors the best basketball players, greatest coaches and other contributors to the game. "The game of basketball has been everything to me ," said Jordan, 46. "It is the place I have always gone when I needed to find comfort and peace." Jordan retired twice in his 15-year career, finishing with 32292 points, the third highest total points in NBA history behind Kareem Abdul-Jabbar and Karl Malone. His average of 30.12 points a game is the best in the League. "One day you might look up and see me playing the game at 50," Jordan said. "Because limits, like fears, are often just an illusion." In other words, it was motivation that made Jordan such a success.. A great career did not mean a smooth one. His high school coach cut him from the team in favor of a taller player when Jordan was in 10thgrade. His college coach wouldn't allow him on the cover of Sports Illustration in 1981 with North Carolina's four other players because Jordan was a freshman. In his first NBA All-Star game, older NBA stars wouldn't throw him the ball because of jealousy. "That burned me up," Jordan said. "But _ don't have to stop you. If you run into a wall, don't turn around and give up. Figure out how to climb it, go through it, or work around it."

Answer: Who scored the highest total points in NBA history?


Question: It is unanimously accepted that there is an unmet need for pain medications that are both effective and safe. Unfortunately, no really novel analgesics have been approved over the past three decades. In view of both experimental and clinical evidence of a major role for nerve growth factor (NGF) in the generation and maintenance of a wide range of pain states, drug discovery efforts focusing on the development of anti-NGF agents have aroused particular interest. Several humanized anti-NGF monoclonal antibodies (mAbs) have entered clinical trials as potential analgesics. In this respect, tanezumab is at an advanced stage of clinical development while fulranumab, fasinumab and ABT-110, previously known as PG110, are in early phases of clinical development. This Current Opinion article aims at describing the rationale for targeting NGF for pain, reviewing the analgesic efficacy and safety of anti-NGF agents based on data from fully published studies, conference abstracts, and the US Food and Drug Administration (FDA) website, and discussing the possible future of these agents in managing chronic pain. Anti-NGF mAbs produced significant pain relief and functional improvement in patients with osteoarthritis of the knee and/or hip. Conversely, studies in non-specific lower back pain generated mixed results; overall, this condition appeared to be less responsive to anti-NGF agents than osteoarthritis. Finally, there was no conclusive evidence of the effectiveness of anti-NGF mAbs in some types of chronic visceral or neuropathic pain. Furthermore, these studies raised safety concerns about anti-NGF mAbs. As a class, these drugs may cause or worsen peripheral neuropathies. But the most problematic issue-which prompted the FDA to place studies of these compounds on clinical hold in 2010-was rapid joint destruction leading to joint replacement surgery. The aetiologies of these side effects have been much debated and their pathophysiology is poorly understood. After an Arthritis Advisory Committee meeting held in March 2012, pharmaceutical companies negotiated with the FDA on the conditions for restarting clinical studies. Although the FDA lifted its clinical hold, there remain many unresolved issues about the long-term efficacy and safety of anti-NGF mAbs. While acknowledging that the future of these drugs is unforeseeable, it appears that they may not be the safe and effective painkillers that have been awaited for decades.

Answer: What is the target of tanezumab?


Question: Susana Machado Bernard House and Barn is an elaborate 10,000-square-foot (930 m2) Art Nouveau Gothic Revival style mansion and carriage house located in the Pico Union section of Los Angeles, California.

Answer:
Of what style is Susana Machado Bernard House and Barn?